Polaryx Therapeutics, Inc.
PLYXCIK 0002075320
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$8.99M
+70.4% YoY
Q1 May 2026
EPS Diluted (TTM)
−$0.20
+77.5% YoY
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$3.08M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
47.34M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.